Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
1.745
+0.005 (0.29%)
Jan 30, 2025, 12:18 PM EST - Market open
Fortress Biotech Revenue
Fortress Biotech had revenue of $14.63M in the quarter ending September 30, 2024, a decrease of -7.13%. This brings the company's revenue in the last twelve months to $81.50M, up 31.51% year-over-year. In the year 2023, Fortress Biotech had annual revenue of $84.51M with 11.58% growth.
Revenue (ttm)
$81.50M
Revenue Growth
+31.51%
P/S Ratio
0.36
Revenue / Employee
$438,177
Employees
186
Market Cap
48.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.95B |
FBIO News
- 3 days ago - Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT - GlobeNewsWire
- 7 days ago - Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea - GlobeNewsWire
- 24 days ago - Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - PRNewsWire
- 24 days ago - Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - GlobeNewsWire
- 6 weeks ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 2 months ago - Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 2 months ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 2 months ago - Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire